Clinical significance of nerve growth factor and tropomyosin-receptor-kinase signaling pathway in intrahepatic cholangiocarcinoma

Table 2 Univariate analysis of clinicopathologic features for overall survival

Clinicopathologic parameters		Median	Survival	P value1
Age	< 65 yr	46.2	39.5%	0.776
	≥ 65 yr	59.9	60.3%
gender	male	46.7	42.6%	0.364
	female	51.5	43.5%
Tumor size	< 5 cm	57.4	50.2%	0.029
	≥ 5 cm	40.6	36.1%
Differentiation	Well	54.5	49.9%	0.587
	Moderately	47.8	40.4%
	Poorly	43.6	40.7%
T stage	T1	52.7	49.0%	0.411
	T2	58.9	60.0%
	T3	33.0	23.4%
	T4	0.0	0.0%
N stage	N0	58.7	53.3%	0.002
	N1	17.6	14.0%
M stage	M0	51.8	45.5%	0.004
	M1	7.8	0.0%
TNM stage	I	62.4	60.4%	0.004
	II	73.0	77.8%
	III	46.6	36.8%
	IV	17.2	13.6%
Satellites	Negative	50.0	47.1%	0.132
	Positive	31.3	31.4%
Macrovascular invasion	Negative	49.7	42.9%	0.290
	Positive	24.3	33.3%
Microvascular invasion	Negative	49.5	43.9%	0.445
	Positive	44.7	41.8%
Intraneural invasion	Negative	47.2	41.5%	0.678
	Positive	55.7	52.5%
NGF	Negative	54.2	49.4%	0.201
	Positive	36.4	29.6%
TrkA	Negative	48.9	42.7%	0.483
	Positive	44.6	41.6%
NGF + TrkA	Negative	53.1	46.5%	0.030
	Positive	18.0	24.6%

¹Log-rank test. NGF: Nerve growth factor; TrkA: Tropomyosin-receptor-kinase.